31 biopharmaceutical companies are now involved in the research and development of psychedelic compounds to treat mental health issues such as obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders. This article tracks the performance of 15 of them in the munKNEE Psychedelic Stocks Index.

Index Inclusion Criteria

The 15 stocks eligible for inclusion in the index are based on the following criteria:

• a market capitalization between US$10M and US$200M
• a stock that trades between US$0.10/share and US$2/share

Below are the 15 eligible companies in the munKNEE Psychedelic Stocks Index and their performance on Thursday, December 17th in descending order. Yesterday's performance for each is in brackets.

1. Champignon (SHRMF) +10.6% (-6.8%)  
2. Hollister (HSTRF) +8.2% (-17.9%) 
3. Numinus (LKYSF) +5.2% (-7.3%) 
4. Mydecine (MYCOF) +5.2% (-7.3%) 
5. Mind Cure (MCURF) +5.2% (-12.7%) 
6. Seelos (SEEL) +4.9% (+6.8%) 
7. Psyched Wellness (DCNPF) +4.0% (-11.7%) 
8. Red Light (TRUFF) +3.5% (-10.8%)
9. Silo Pharma (SILO) +3.3% (+2.3%) 
10. Cybin (CLXPF) +1.6% (+5.7%)
11. Nova Mentis (LIBFF) N/C (-11.1%) 
12. Revive (RVVTF) N/C (+3.2%) 
13. Havn (HAVLF) -1.5% (+8.5%)
14. Better Plant (VEGGF) -8.4% (-7.3%) 
15. Jaguar (JAGX) -16.3% (+5.8%)

The average performance of the above 15 psychedelic drug stocks on Thursday was +2.7% vs. +9.3% on Wednesday, -15.9% on Tuesday and +27.2% on Monday. Interestingly, in comparison, the munKNEE Pure-Play Pot Stock Index of the 25 pure-play cannabis stocks that trade in excess of US$1/share was -0.3% on Thursday compared to +2.6% on Wednesday, +2.2% on Tuesday and -2.3% on Monday. To avoid duplication please refer to a previous article (see here) in which I provided introductory paragraphs on each of the above constituents.